Selection of in vitro models that accurately characterize metabolite systemic and hepatobiliary exposure remains a challenge in drug development. In the present study, mechanisms underlying differences in systemic exposure of two active metabolites, furamidine and 2, 5-bis (5-amidino)-2-pyridyl) furan (CPD-0801), were examined using two hepatic models from rats: isolated perfused livers (IPLs) and sandwich-cultured hepatocytes (SCH).
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INTRODUCTION
The liver often is the predominant organ for biotransformation of a precursor compound (i.e., prodrug) to active metabolite, which can influence therapeutic and/or toxicologic outcomes (Pang et al., 2008) . Once formed, active metabolite can undergo further metabolism, excretion into systemic circulation or bile, and/or intrahepatic sequestration. Accurate characterization of the systemic and hepatobiliary exposure of active metabolite is, therefore, imperative for efficacy and risk assessment. Although physiologically relevant, in vivo studies are cumbersome, costly, and associated with a variety of extrahepatic variables, including metabolic and active uptake/efflux processes in the intestine and kidney. As an alternative methodology, in vitro or ex vivo hepatic models that have strong descriptive and predictive capabilities for the in vivo situation would offer significant advantages.
Isolated perfused livers (IPLs) are considered the closest approximation to the hepatobiliary system in vivo due to maintenance of hepatic architecture, microcirculation, and bile production (Brouwer and Thurman, 1996) . Biotransformation pathways, sinusoidal/biliary transport processes, mechanisms underlying drug-drug interactions, and alterations in physiology (blood flow or changes in protein binding that might be associated with disease) can be elucidated by manipulating experimental conditions, in the absence of extrahepatic influence.
Despite these advantages, several shortcomings limit widespread use of IPLs, such as the delicate surgical techniques required, the relatively short experimental period in which viability is maintained (≤ 2h), and the time/labor-intensive nature of the procedure (Brouwer and Thurman, JPET#177220 6 metabolites ( Fig. 1) (Zhou et al., 2004; Generaux, 2010) . Once formed, active metabolites must be excreted from hepatocytes into the systemic circulation to exert antiparasitic activity. These observations led to the hypothesis that improved efficacy of the prodrug, CPD-0868, against second stage infection compared to pafuramidine reflects superior hepatobiliary disposition characteristics, including a greater extent of conversion to the active metabolite and/or more efficient excretion of CPD-0801 from hepatocytes into the systemic circulation. This hypothesis was addressed utilizing IPLs and SCH from rats, coupled with mathematical modeling, to elucidate mechanisms underlying the difference in systemic/hepatobiliary exposure of these two antiparasitic active metabolites. Results generated from SCH were compared with IPLs.
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8 was collected at 10-min intervals; liver was harvested at the end of perfusion. Perfusate, bile, and liver collections were stored at -80°C pending analysis for prodrug and derived metabolites by liquid chromatography with detection by tandem mass spectrometry (LC-MS/MS). The prodrug concentration (10 µM) was based on solubility in perfusate and assay sensitivity to monitor prodrugs/metabolites in perfusate, liver, and bile throughout the 2-h experimental period. The absence-of-liver condition was used to assess nonspecific binding of prodrug and metabolites to the IPL apparatus.
Determination of Unbound Fraction. Liver. Livers from IPL experiments (described above) were thawed and homogenized in three volumes (v/w) of 0.1 M phosphate buffered saline (PBS). The unbound fraction of formed active metabolite in liver homogenates was determined using rapid equilibrium dialysis devices (Pierce Biotechnology, ThermoFisher Scientific, Waltham, MA). Liver homogenates (350 μ l) and blank PBS (200 μ l) were placed in tissue and buffer chambers, respectively, and incubated (37°C) for 6 h on a thermomixer (350 rpm) (Eppendorf AG, Hamburg, Germany). Preliminary testing indicated that 6 h of incubation was sufficient to achieve equilibrium without significant compound degradation. After 6 h, aliquots (100 µl) were collected from the tissue and buffer chambers and analyzed for total (bound+unbound) and unbound formed active metabolite, respectively, by LC-MS/MS. Perfusate/Plasma. Blank rat IPL perfusate (composed of 20% rat blood) and plasma were spiked with preformed active metabolite to yield a total concentration of 1 or 10 and 0.1% formic acid in HPLC-grade methanol (B) delivered by a Shimadzu pumping system (Shimadzu, Kyoto, Japan) at a flow rate of 0.75 ml/min as follows: after a 0.5-min initial hold at 10% B, mobile phase composition was increased from 10% to 90% B over 3.5 min, and held at 90% B for 0.5 min; the column was re-equilibrated for 0.5 min before the next injection. For all studies except liver binding, prodrugs and metabolites were quantified with calibration standards
(1-10,000 nM) prepared in the appropriate matrix; for the liver binding study, both active metabolites were quantified with calibration standards prepared in liver homogenates (0.5-50 µM) and PBS (1-10,000 nM). All calibration curves were linear over the respective range (R 2 > 0.98). Intra-and Inter-day coefficients of variation were <15%. the ratio of concentration in cells (C C ) to that in medium (C M ) at the end of the incubation (24 h).
The hepatocellular volumes used to calculate C L and C C were 0.6 ml/g rat liver (Pang et al., 1988) compared to furamidine. The area under the perfusate concentration-time curve (AUC) for CPD-0801 was 10-fold higher than that for furamidine (Table 3) . Pharmacokinetic modeling (Model 1, Fig. 2 ) revealed that the rate constant associated with net basolateral efflux (k A_net efflux ) of CPD-0801 was 6-fold higher than that of furamidine (Table 2 ).
Hepatic accumulation of both active metabolites in rat IPLs was extensive (Table 3 ). The liver-to-perfusate partition coefficient (K p , IPLs ) of furamidine at 2 h was 3700 and was approximately 5-fold higher than that of CPD-0801 (Table 3 ). The unbound fractions of both active metabolites in plasma/perfusate were similar at 1 and 10 µM. The unbound fraction of each active metabolite in rat liver (f u,L ) was ≥ 24-fold lower than that in plasma (f u,P ) and perfusate (composed of 20% rat blood; f u,Per ) ( Table 3) . The f u,L of CPD-0801 was approximately 5-fold higher than that of furamidine ( Table 3 ). Assuming that only unbound drug can translocate out of hepatocytes into blood and bile, f u,L was incorporated into the pharmacokinetic model (Model 2, Fig. 2 ) to evaluate further the hepatic excretion of derived active metabolite.
Based on Model 2, the rate constant for biliary excretion (k A_bile,u ) was 9-fold higher than that of basolateral efflux (k A_net efflux,u ) for unbound furamidine (Table 4) , whereas k A_bile,u and k A_net efflux,u for CPD-0801 were more comparable than those for furamidine (Table 4) . After incorporating f u,L , the k A_net efflux,u of furamidine became comparable to that of CPD-0801 (Table 4) .
Disposition of Prodrugs/Metabolites in Day-4 Sandwich-Cultured Rat Hepatocytes.
The disposition profiles of prodrugs and derived metabolites in SCH (Fig. 5 ) were similar to those for rat IPLs (Fig. 3) , although the time-course in SCH was longer than that in IPLs (24 vs.
h).
As shown in IPLs, the recovery of M1 and M2 metabolites of pafuramidine in medium, cells, and bile was BLQ; the M3 metabolite of pafuramidine appeared in medium immediately ( Fig.   5A ), reflecting M3 as an impurity. The M1 metabolite of CPD-0868 in medium was maximal at 2 h ( Fig. 5B) , and then decreased rapidly due to subsequent reuptake into hepatocytes and metabolism. The M3 metabolite of CPD-0868 in medium was maximal at 8 h (Fig. 5B ), then decreased due to reuptake into hepatocytes and further metabolism. The rate constant associated with conversion from M3 to the active metabolite (k M3→A ) of CPD-0868 was 1.4-fold higher than that of pafuramidine (Table 5) . Only the M3 metabolite of CPD-0868 was recovered in bile (Table 5 ).
The extent of conversion of CPD-0868 to CPD-0801 was consistently higher than that of pafuramidine to furamidine in SCH over 24 h (Fig. 4B) . Medium exposure to CPD-0801 was higher compared to furamidine. The area under the medium concentration-time curve (AUC) for CPD-0801 was 7-fold higher than that for furamidine ( Table 3) . As shown in IPLs, k A_net efflux of CPD-0801 was 6-fold greater than that of furamidine. Model 1 adequately described the disposition of furamidine in medium and hepatocytes (solid and dashed lines in Fig 5A) ; the large variability in the parameter estimate for k A_net efflux of furamidine may be due to the marked difference between the amount of furamidine recovered in the medium and that recovered in hepatocytes (>2 orders of magnitude). Hepatocellular accumulation of furamidine and CPD-0801 over 24 hr was extensive (Table 3 ). The cell-to-medium partition coefficients of both active metabolites measured in SCH (K p,SCH ) was >6-fold higher than corresponding values measured in IPLs (K p,IPLs ); similar to IPL results, K p,SCH of furamidine was approximately 6-fold higher than that of CPD-0801 (Table 3) .
Effect of Prodrugs/Metabolites on Hepatocyte Viability. In rat SCH treated with vehicle (0.1% DMSO) or prodrug (pafuramidine or CPD-0868), an elevation in LDH release was not observed over 24 h compared to untreated SCH (data not shown). These data suggested that membrane integrity remained intact as a function of prodrug treatment and time.
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 3 vs. Fig. 5 ). The extent of formation and AUC in perfusate (IPLs) or medium (SCH) of CPD-0801 was consistently higher than that of furamidine (Table 3) . A stepwise pharmacokinetic modeling approach was utilized to differentiate, quantitatively, between the contribution of hepatic metabolism and transport to the enhanced perfusate/medium AUC of CPD-0801 compared to furamidine. Model 1 described adequately the disposition of both prodrugs and derived metabolites ( Fig. 3 and Fig. 5 ; Supplemental Fig.   S1 and Fig. S2 ) and predicted a net basolateral efflux rate constant (k A_net efflux ) for CPD-0801 that was 6-fold higher than that for furamidine in both IPLs (Table 2 ) and SCH (Table 5 ). The extent of formation of CPD-0801 was only ≤ 2.5-fold higher than that of furamidine ( Fig. 4A and Fig. 4B ; Table 3 ). These observations indicated that net basolateral efflux predominated over metabolism in governing perfusate/medium exposure to active metabolite.
The f u,L of CPD-0801 was ~5-fold higher than that of furamidine. Based on Model 2 (Fig. 2), the ratio of biliary excretion (k A_bile,u ) to basolateral efflux (k A_net efflux,u ) rate constants for furamidine was 9 ( Table 4 ), suggesting that once formed in liver, the predominant process that determines furamidine elimination is excretion into bile, whereas biliary and basolateral excretory processes contribute approximately equally to CPD-0801 hepatic excretion (Table 4) .
Incorporation of f u,L in Model 2 (Fig. 2) resulted in a comparable k A_net efflux,u of both active metabolites ( Table 4 ), indicating that the 6-fold difference in the rate constant for net basolateral efflux of total formed active metabolite (k A_net efflux ) could be attributed largely to the 5-fold difference in hepatic binding. In rats administered a single oral dose of pafuramidine (10 mg/kg), liver-to-plasma partitioning (K p ) of furamidine was as high as 1300 (Midgley et al., 2007) . As shown in the current study, hepatic accumulation of furamidine was extensive, and the unbound fraction of furamidine in liver was much lower than that in plasma and perfusate (Table 3) . Thus, binding sites in liver may act as an "intracellular sink" that limit systemic exposure to furamidine. Previous subcellular fractionation studies demonstrated that furamidine accumulated primarily in the mitochondrial fraction of liver tissue (Midgley et al., 2007) . Consistent with these observations, preliminary fractionation studies with rat IPLs revealed that furamidine was localized primarily in the mitochondrial fraction (43%) in rat IPLs; CPD-0801 was localized primarily in the cytosolic fraction (45%), with negligible mitochondrial accumulation (≤1%) (unpublished observations).
Extensive accumulation of furamidine in mitochondria could cause mitochondrial dysfunction and trigger hepatotoxicity (Pessayre et al., 1999) . Significant hepatic accumulation of furamidine is consistent with previous in vivo data (Midgley et al., 2007) suggesting that hepatocellular sequestration may limit systemic exposure of furamidine and predispose the liver to toxicity. In contrast, a significantly higher hepatic unbound fraction and less mitochondrial accumulation of CPD-0801, compared to furamidine, could enhance systemic exposure to CPD-0801 and reduce hepatotoxic potential.
Utilizing appropriate preclinical hepatic models to estimate liver-to-plasma partitioning of potential hepatotoxicants has been a topic of interest in toxicologic risk assessment. In the current study, the liver-to-perfusate partition coefficient (K p,IPLs ) of furamidine measured in IPLs was 3700, about 2.8-fold higher than the in vivo K p (1300) measured in rats. This discrepancy can be explained by the 2-fold difference in the extent of protein binding of furamidine in perfusate (composed of 20% blood) vs. plasma (Table 3) This discrepancy could be explained, in part, by the absence of serum in culture medium, which resulted in a higher f u in medium (approximately unity) than that in perfusate. Therefore, binding differences in transport buffer/medium and plasma need to be considered when using SCH to estimate liver-to-plasma partitioning. Nonetheless, both K p , SCH and K p,IPLs of furamidine were >5-fold higher than those of CPD-0801.
The intermediate metabolite, M3, from both prodrugs was excreted extensively into bile in IPLs; M3 from CPD-0868 was the most extensively excreted compound in bile among all prodrugs and metabolites. Both active metabolites also were recovered in bile, but to a 20-to 50-fold lesser extent than M3 from CPD-0868 (Table 2 ). In contrast, only M3 from CPD-0868 was recovered in bile of SCH. Unlike in IPLs, biliary excretion in SCH was measured indirectly, by determining the difference in substrate accumulation between standard HBSS (cells+bile) and Ca 2+ -free HBSS (cells) (Liu et al., 1999b) . As reported previously, SCH may under-predict in vivo biliary clearance of compounds due to less extensive canalicular network formation relative to whole liver (Liu et al., 1999b; Hoffmaster et al., 2005; Abe et al., 2008) . To compare the biliary excretion in SCH and in IPLs, the intrinsic biliary clearance of M3 from CPD-0868 in SCH (Cl M3_biliary, SCH ) was estimated by multiplying k M3_bile (Table 5 ) by the hepatocellular volume of 6.2 × 10 -6 µl/hepatocyte (Swift et al., 2009) , and then scaled up to l/h/g liver based on 110 × 10 6 hepatocytes/g rat liver (Ito and Houston, 2004) and 1 × 10 6 hepatocytes/well in 6-well plates.
The intrinsic biliary clearance of M3 from CPD-0868 in IPLs (Cl M3_biliary, IPLs ) was estimated by multiplying k M3_bile (Table 2) by the hepatocellular volume of 0.6 ml/g rat liver (Pang et al., 1988) . Table 3 ); in addition, k A_bile of furamidine and CPD-0801 was 20-to 50-fold lower compared to M3 (k M3_bile ) from CPD-0868 (Table 2) . Therefore, biliary excretion of furamidine/CPD-0801 may be so small that the difference in substrate accumulation between standard and Ca 2+ -free HBSS was indistinguishable.
A previous study showed that CYP4F2 and CYP4F3B were the major enzymes 
